Insights

Niche Market Focus Aceragen specializes in developing therapies for rare and orphan diseases, positioning it as a key player in an underserved market segment with high unmet medical needs, presenting opportunities for partnerships with specialists and institutions focused on rare disease treatments.

Growth Potential With a current funding of 35 million dollars and a revenue range of 1 to 10 million dollars, Aceragen shows signs of growth and development, creating opportunities to support their pipeline advancement and commercialization efforts.

Regulatory and Community Engagement The company's focus on community awareness and regulatory outreach efforts indicates openness to collaborations that can enhance market adoption, patient engagement, and educational initiatives in rare disease communities.

Technological Infrastructure Aceragen's use of multiple technology stacks including WordPress, MySQL, and cloud services suggests a scalable digital platform that can support partnerships in research, data sharing, and patient engagement strategies.

Strategic Delisting The recent voluntary delisting from Nasdaq and potential asset transfer plan indicates a transitional phase, offering opportunities to explore investment, acquisition, or partnership prospects during this strategic shift.

Similar companies to Aceragen

Aceragen Tech Stack

Aceragen uses 8 technology products and services including cdnjs, RSS, Open Graph, and more. Explore Aceragen's tech stack below.

  • cdnjs
    Content Delivery Network
  • RSS
    Content Management System
  • Open Graph
    Content Management System
  • WordPress
    Content Management System
  • MySQL
    Database
  • jQuery
    Javascript Libraries
  • Amazon ALB
    Load Balancers
  • OpenResty
    Web Servers

Aceragen's Email Address Formats

Aceragen uses at least 1 format(s):
Aceragen Email FormatsExamplePercentage
FLast@aceragen.comJDoe@aceragen.com
50%
FLast@aceragen.comJDoe@aceragen.com
50%

Frequently Asked Questions

What is Aceragen's stock symbol?

Minus sign iconPlus sign icon
Aceragen is a publicly traded company; the company's stock symbol is ACGN.

What is Aceragen's official website and social media links?

Minus sign iconPlus sign icon
Aceragen's official website is aceragen.com and has social profiles on LinkedIn.

What is Aceragen's SIC code NAICS code?

Minus sign iconPlus sign icon
Aceragen's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Aceragen have currently?

Minus sign iconPlus sign icon
As of December 2025, Aceragen has approximately 11 employees across 1 continents, including North America. Key team members include Chief Financial Officer: A. J.. Explore Aceragen's employee directory with LeadIQ.

What industry does Aceragen belong to?

Minus sign iconPlus sign icon
Aceragen operates in the Biotechnology Research industry.

What technology does Aceragen use?

Minus sign iconPlus sign icon
Aceragen's tech stack includes cdnjsRSSOpen GraphWordPressMySQLjQueryAmazon ALBOpenResty.

What is Aceragen's email format?

Minus sign iconPlus sign icon
Aceragen's email format typically follows the pattern of FLast@aceragen.com. Find more Aceragen email formats with LeadIQ.

How much funding has Aceragen raised to date?

Minus sign iconPlus sign icon
As of December 2025, Aceragen has raised $35M in funding. The last funding round occurred on May 03, 2021 for $35M.

When was Aceragen founded?

Minus sign iconPlus sign icon
Aceragen was founded in 2021.

Aceragen

Biotechnology ResearchNorth Carolina, United States11-50 Employees

Aceragen is a rare disease biopharmaceutical company. We address rare, orphan diseases that typically have no available treatment, and strive to develop novel therapies which can have a positive impact on the lives of patients and families. As such, the needs of the patients who suffer from neglected rare diseases drive our mission first-and-foremost. Our goal is to provide rare-disease patients with compelling new therapeutic options that will allow them to lead the fullest lives possible. Such diseases have been frequently overlooked for drug development and remain “orphan” due to the assumption that they have a small individual footprint. We aim to change this outlook, engaging in community awareness, regulatory outreach, and most importantly, delivering novel treatments. By focusing on rare and orphan diseases, we hope to bring a much-needed spotlight to the area by leveraging our collective conviction that these efforts will change the world for the better.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ACGN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2021
Employees
11-50

Section iconFunding & Financials

  • $35M

    Aceragen has raised a total of $35M of funding over 1 rounds. Their latest funding round was raised on May 03, 2021 in the amount of $35M.

  • $1M$10M

    Aceragen's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $35M

    Aceragen has raised a total of $35M of funding over 1 rounds. Their latest funding round was raised on May 03, 2021 in the amount of $35M.

  • $1M$10M

    Aceragen's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.